ALEC vs BIIB
ALEC: An early-stage biotech company developing novel therapeutic candidates for neurodegenerative diseases through preclinical research and clinical trials. BIIB: Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
Side-by-side fundamentals
| Metric | ALEC | BIIB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.53 | $197.74 | |
| Market cap as of 2026-07-23 | $169M | $29.8B | |
| P/E as of 2026-07-23 | n/a | 21.75 | |
| PEG as of 2026-07-23 | n/a | 10.24 | |
| Net margin as of 2026-07-23 | -680.8% | +13.8% | BIIB higher |
| Gross margin as of 2026-07-23 | n/a | +75.5% | |
| Operating margin as of 2026-07-23 | -739.7% | +17.5% | BIIB higher |
| ROE as of 2026-07-23 | -295.2% | +7.5% | BIIB higher |
| ROA as of 2026-07-23 | -40.9% | +4.7% | BIIB higher |
| Debt / equity as of 2026-07-23 | 0.94 | 0.34 | BIIB lower |
| Revenue growth (YoY) as of 2026-07-23 | -79.2% | +1.2% | BIIB higher |
| Revenue CAGR (3y) SEC XBRL | -46.0% | -0.9% | BIIB higher |
| Beta as of 2026-07-23 | 0.57 | 0.16 | |
| 1-year return as of 2026-07-22 close | -11.0% | +54.7% | BIIB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.